Advertisement
Evotec, Novo Nordisk Roll Out LAB EN To Accelerate Translation In Cardiometabolic Diseases
(RTTNews) - Evotec SE (EVO, EVOTF.PK) and Novo Nordisk A/S (NVO) announced Tuesday a translational drug discovery accelerator called LAB eN, which aims to nurture early research from academic institutions into novel therapeutics.
LAB eN is a unique engagement model that combines Evotec's multimodality drug discovery and pre-clinical development capabilities with Novo Nordisk's therapeutic, clinical, and commercial expertise.
LAB eN will focus on addressing unmet need in cardiometabolic diseases as well as rare blood and rare endocrine disorders.
LAB eN has already signed on four academic institutions to participate: Harvard University, Mass General Brigham, Yale University, and Beth Israel Deaconess Medical Center.
read more
Novo Nordisk Stock Climbs On Higher Q1 Results; Cuts FY25 Outlook
Shares of Novo Nordisk A/S were gaining around 6 percent in Denmark as well as around 7 percent in the pre-market activity on the NYSE, after the Danish drug major reported Wednesday higher profit and sales in its first quarter, mainly reflecting improved results of its blockbuster weight loss drug Wegovy. Meanwhile, the company trimmed fiscal 2025 outlook for sales and operating profit growth...
RTTNews
|
Před 5 dny
Novo Nordisk Plans $4.1 Bln NC Facility To Boost Obesity Drug Supply
Danish drug maker Novo Nordisk announced its plans to invest $4.1 billion or about 27 billion Danish kroner to build a new manufacturing plant in Clayton, North Carolina with a view to expanding its manufacturing capacity in the United States. In the new plant, the company plans to produce current and future injectable treatments for people with obesity and other serious chronic diseases.
RTTNews
|
Před 321 dny
Novo Nordisk Says FLOW Trial Achieves Primary Endpoint
Novo Nordisk A/S (NVO) announced Tuesday the headline results from the kidney outcomes trial FLOW. The announcement follows the decision to stop the trial early due to efficacy.
RTTNews
|
Před 433 dny
Novo Nordisk Slashes US List Prices Of Several Insulin Products By Up To 75%
Healthcare company Novo Nordisk Inc. (NVO) announced Tuesday it is lowering the U.S. list prices of several pre-filled insulin pens and vials by up to 75% for people living with type 1 and type 2 diabetes.
RTTNews
|
Před 790 dny
Dollar Extends Gains As Trade Tensions Ease
It was another positive week for the greenback as easing trade tensions and hopes of a deal with China helped the U.S. Dollar build on gains made in the previous week.
RTTNews
|
Před 1 h 40 min
Fox Q3 Profit Down, Revenues Climb, Both Ahead Of Market; Stock Gains
Media firm Fox Corp. reported Monday weak earnings in its third quarter on higher expenses, while revenues were higher, benefited mainly by advertising revenue growth of 65 percent, primarily due to the impact of Super Bowl LIX. Adjusted earnings and top line beat market estimates. In pre-market activity on the Nasdaq, the FOX shares were gaining around 3.8 percent.
RTTNews
|
Před 3 h 22 min
Bay Street Likely To Open On Firm Note
The Canadian market is likely to open with a strong positive gap on Monday, tracking gains in global markets amid easing tariff concerns following China and the U.S. striking a deal over the weekend.
RTTNews
|
Před 3 h 45 min
U.S., China Reach Agreement To Slash Tariffs
Following closely watched meetings over the weekend in Geneva, Switzerland, the U.S. and China have announced an agreement to drastically reduce tariffs on each other's goods. The White House said the agreement calls for the U.S. and China to each lower tariffs by 115 percent while retaining an additional 10 percent tariff.
RTTNews
|
Před 4 h 22 min
